
KEYTRUDA® (pembrolizumab) - Official Site
Learn about KEYTRUDA® (pembrolizumab), an immunotherapy that works with your immune system to help fight certain cancers. Visit the patient website.
How KEYTRUDA® (pembrolizumab) Works
Learn how KEYTRUDA® (pembrolizumab) works with your immune system to help fight cancer cells. Watch two videos about immunotherapy and how it works in the body.
Side Effects of KEYTRUDA® (pembrolizumab)
Learn about the side effects that may occur while taking KEYTRUDA® (pembrolizumab). Review serious side effects and common side effects with KEYTRUDA.
How KEYTRUDA® (pembrolizumab) Is Given
See how long treatment administration with KEYTRUDA® (pembrolizumab) may take, explore your options for receiving it, and learn what to expect during the process.
FAQs About KEYTRUDA® (pembrolizumab)
Find answers to frequently asked questions about KEYTRUDA® (pembrolizumab) including how does KEYTRUDA work, PD-L1 testing information, and more.
Infusion Information and Resources for KEYTRUDA® …
View tips and resources that may help while receiving KEYTRUDA® (pembrolizumab) including what to expect with your first infusion appointment and what to know about your treatment …
Subcutaneous Injection | KEYTRUDA QLEX™ (pembrolizumab and ...
Learn about KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), an immunotherapy treatment. Talk to your doctor to find out more.
Early-Stage Melanoma (Stage 2B or 2C) Through Advanced
KEYTRUDA is a medicine that may treat certain cancers by working with your immune system. KEYTRUDA can cause your immune system to attack normal organs and tissues in any area …
COST, INSURANCE & FINANCIAL HELP - KEYTRUDA
Learn about cost information, insurance, and potential financial assistance options with KEYTRUDA® (pembrolizumab). See more at keytruda.com.
Triple-Negative Breast Cancer (TNBC) - KEYTRUDA
How is TNBC treated with KEYTRUDA? KEYTRUDA is an immunotherapy that works with your immune system to help treat certain cancers. If you have early-stage breast cancer and are at …